Publications by authors named "Tatsuhiro Kataoka"
This study examined the anti-inflammatory and endothelial function-enhancing effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor therapy in the early phase after acute myocardial infarction (AMI) by assessing changes in tumor necrosis factor-α (TNF-α) levels and the L-arginine/asymmetric-dimethylarginine (ADMA) ratio. This retrospective, single-center cohort study included patients who underwent successful timely primary percutaneous coronary intervention (PCI) for first-onset AMI between September 2017 and March 2018. The PCSK9 inhibitor group comprised patients who received 75 mg alirocumab up to 7 days after AMI, while the standard therapy group comprised patients who did not.
View Article and Find Full Text PDFBackground And Aims: The short-term (within 6 weeks) effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on lipid plaques have not been adequately evaluated. We aimed to investigate whether a single dose of a PCSK9 inhibitor before percutaneous coronary intervention (PCI) could reduce the abundance of lipid-core plaques identified via near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) at target lesions within a very short period.
Methods: This prospective, single-arm, single-center interventional study enrolled 27 consecutive patients with coronary artery disease.
Background: In coronary artery disease (CAD), lipid-core-containing plaque (LCP) in nontarget lesions detected using near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) was related to increased major adverse cardiovascular events in patients with CAD. In the endovascular therapy field, few previous studies using NIRS-IVUS revealed the presence of LCPs in severe stenotic lesions of femoropopliteal disease.
Aim: This study aimed to assess the plaque morphology of nontarget lesions, especially LCPs, and compare it with that of target lesions using NIRS-IVUS in patients with femoropopliteal disease.
Article Synopsis
- This study investigates the impact of catheter ablation on various biomarkers, particularly focusing on uric acid (UA), glucose, and lipid metabolism in atrial fibrillation (AF) patients.
- A total of 206 AF patients were analyzed, showing significant decreases in both uric acid and brain natriuretic peptide (BNP) levels one year after the procedure, with persistent AF patients experiencing a more notable decline in UA levels.
- The findings suggest that ablation is effective in improving UA levels in AF patients without negatively affecting heart function or kidney health, indicating its potential benefits for those with high UA levels prior to the procedure.
Background: The left atrial appendage closure (LAAC) device for patients with nonvalvular atrial fibrillation (NVAF) has recently been introduced in Japan. However, clinical data of Japanese patients are insufficient.
Methods: In this single-center study, 55 consecutive patients (mean age, 74 years) who received LAAC therapy from September 2019 to December 2020 were analyzed.